BI 1356225

DRUG3 trials

Sponsors

Boehringer Ingelheim

Conditions

HealthyObesityOpioid Use Disorder

Phase 1

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225

CompletedNCT04065295

Boehringer IngelheimHealthy

Start: 2019-09-09End: 2019-12-23Updated: 2022-12-14

A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight

CompletedNCT04447261

Boehringer IngelheimObesity

Start: 2020-06-30End: 2021-04-25Updated: 2021-05-19

A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine

TerminatedNCT06628622

Boehringer IngelheimOpioid Use Disorder

Start: 2025-01-27End: 2026-07-16Updated: 2026-07-31